Glenmark Pharma slashes price of breast cancer drug Trastuzumab

Glenmark Pharmaceuticals Ltd said on Thursday that it has lowered the price of its breast cancer drug Trastuzumab by offering its brand Trumab at Rs 15,749 for a 440mg vial from Rs 54,000 earlier.

Trastuzumab is used to treat a certain type of breast cancer – HER2-positive, and the company is marketing its version in India under the brand name ‘Trumab’.

“The new price of the drug, which is being marketed under the brand name ‘Trumab’, will be 15,749 rupees per 440-mg vial. This price cut will bring the cost per mg of Traumab to around 35 rupees, making it the most affordable treatment option for the drug,” Glenmark said. In a statement, “The HER2-positive breast cancer in the country.”

Most of the Trastuzumab brands currently in the market are priced between Rs 40,000 to Rs 54,000 per 440mg vial, the company said, adding that the cost of Trastuzumab treatment has been a major constraint for many patients in India.

“Considering that a patient needs to undergo at least 18 cycles (12 months) of treatment, the average cost of treatment ranges from Rs 4 lakh to Rs 5 lakh for early breast cancer and can exceed Rs 5 lakh for advanced/metastatic cases. , “he added.

Glenmark Pharmaceuticals executive vice president and head of formulations India, Alok Malik, said the company’s move to lower the cost of its life-saving drug Trumab is a major step towards its goal of providing access to quality healthcare to everyone, regardless of their financial situation.

“This will not only increase accessibility, but also bring hope to the more than 75 per cent HER2-positive breast cancer patients who self-pay in India,” he added.

(Only the title and image for this report may have been reworked by the Business Standard staff; the rest of the content is generated automatically from a shared feed.)

First published: June 15, 2023 | 10:45 p.m ist